Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Hess

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Haematologica|June 1, 2023
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L Crombie, Caron A Jacobson, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2021
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaVincent Ribrag, Seung Tae Lee, David Rizzieri, et al.
Emerging Infectious Diseases|April 18, 2018
Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USAAbigail L Carlson, Daniel M Pastula, Amy J Lambert, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
The Lancet. Oncology|May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPaolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Blood Advances|October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trialMehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|October 16, 2008
Development and results of the first ABMS subspecialty Certification Examination in Sleep MedicineStuart F Quan, Richard B Berry, Daniel Buysse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2015
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell LymphomasMaximillian Rosario, Bai Liu, Lin Kong, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Blood Advances|March 3, 2022
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Allison C Rosenthal, Jennifer L Crombie, et al.
Haematologica|June 1, 2023
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L Crombie, Caron A Jacobson, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2021
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaVincent Ribrag, Seung Tae Lee, David Rizzieri, et al.
Emerging Infectious Diseases|April 18, 2018
Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USAAbigail L Carlson, Daniel M Pastula, Amy J Lambert, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
The Lancet. Oncology|May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPaolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Blood Advances|October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trialMehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|October 16, 2008
Development and results of the first ABMS subspecialty Certification Examination in Sleep MedicineStuart F Quan, Richard B Berry, Daniel Buysse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2015
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell LymphomasMaximillian Rosario, Bai Liu, Lin Kong, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Pageof 5